Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK’s Anoro Ellipta Heads To FDA Panel With Higher Hopes For Higher Dose

This article was originally published in The Pink Sheet Daily

Executive Summary

The lead LAMA/LABA combination for COPD will be reviewed at the Sept. 10 session of the Pulmonary-Allergy Drugs Advisory Committee.

You may also be interested in...



GSK Anoro Ellipta Appears Poised For Smooth Advisory Panel; Is First LAMA/LABA On Horizon?

Candidate for first-approved LAMA/LABA combination for COPD heads to the Pulmonary-Allergy Drugs Advisory Committee as FDA questions whether safety is even a concern.

Breo Inverts Traditional Path To COPD Indication For LABA Combinations

GlaxoSmithKline’s NDA for Breo Ellipta sought a COPD indication without prior approval of the combination product or its individual inhaled corticosteroid and long-acting beta agonist components in asthma. A broad development program with extensive dose finding won over a skeptical FDA.

GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims

Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZeneca’s Symbicort.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel